Read More

Genomics firm Twist Bioscience’s Momentum To Continue Throughout 2024, Analyst Says

Twist Bioscience reports strong Q2 earnings, with sales up 25% YoY to $75.3M and orders increasing by 45%. Gross margin expands to 41%. Fiscal year guidance was raised, and William Blair sees continued growth momentum. Analysts reaffirm Outperform ratings.

TWST

Read More

Alignment Healthcare Is ‘Differentiated With Durable Long-Term Growth Trajectory’ In Challenging Medicare Advantage Environment: Analyst Says

Alignment Healthcare earnings: EPS loss $(0.25), sales surge 43.1% to $628.6M, beats guidance. Health plan membership up 50.5% Y/Y. Q2 revenue guidance: $625M-$635M. FY 2024 sales raised to $2.495B-$2.525B. Expert outlook: Favorable Q1, stable cost trends.

ALHC

Read More

Newly Listed Migraine-Focused AEON Biopharma Stock Plunges On Friday – Read Here Why

Preliminary results of AEON Biopharma's Phase 2 trial for chronic migraine treatment reveal no significant improvement over placebo. Despite anticipated reductions in monthly migraine days, statistical significance was not reached, prompting a review of development strategies and financial measures.

AEON